Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mo-Rez · 1 trial · 1 indication
ORR is defined as the percentage of participants with a best overall confirmed (BOR) of Partial Response (PR) or better per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| Module 1 (Mo-Rez +Dostarlimab) Endometrial Cancer | EXPERIMENTAL | - |
| Module 2 (Mo-Rez +/-Bevacizumab) Ovarian Cancer | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Mo-Rez | DRUG | Mo-Rez will be administered intravenously (IV). |
| Dostarlimab | DRUG | Dostarlimab will be administered IV. |
| Bevacizumab | DRUG | Bevacizumab will be administered IV. |
Inclusion Criteria: * Participants must be 18 years of age inclusive or older, at the time of signing the informed consent, or the legal age of consent in the jurisdiction in which the study is taking place. * Participant capable of giving signed informed consent including compliance with the requi...
Mo-Rez is an investigational small molecule being developed for the treatment of tumours, including gynecological tumours. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Mo-Rez is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
Mo-Rez is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The ongoing Phase 1 trial is actively recruiting participants to study the drug in combination with other anti-cancer therapies.
Mo-Rez is being studied in a Phase 1 clinical trial with the identifier NCT06796907, titled 'A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)'. This trial is recruiting participants with tumours, including gynecological tumours, and is enrolling approximately 305 patients across multiple countries.
Yes, Mo-Rez is also known as Mocertatug Rezetecan. The clinical trial NCT06796907, which studies this drug, uses the name Mocertatug Rezetecan in its title. Both names refer to the same investigational drug being developed by GSK.